Together, these data demonstrate that SpiD3 treatment enhanced extracellular ATP and HMGB1 release from CLL cells, in a dose-dependent fashion, substantiating the capacity of CLL cells to establish a chemotactic gradient for immune cell recruitment in the propagation of ICD. The gene discussed is HMGB1; the disease is B-cell chronic lymphocytic leukemia.